Joan Merrill to B-Lymphocytes
This is a "connection" page, showing publications Joan Merrill has written about B-Lymphocytes.
Connection Strength
0.614
-
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
Score: 0.130
-
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
Score: 0.108
-
Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol. 2014 Dec; 66(12):3404-12.
Score: 0.103
-
Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis. 2012 Jan; 71(1):136-42.
Score: 0.083
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.073
-
Immunologic findings precede rapid lupus flare after transient steroid therapy. Sci Rep. 2019 06 13; 9(1):8590.
Score: 0.035
-
Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol. 2015 Feb 01; 194(3):940-9.
Score: 0.026
-
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 2012 Nov; 64(11):3695-705.
Score: 0.022
-
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum. 2009 Apr; 60(4):1076-84.
Score: 0.017
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.017